The health system impact of false positive newborn screening results for medium-chain acyl-CoA dehydrogenase deficiency: a cohort study. Issue 1 (December 2016)
- Record Type:
- Journal Article
- Title:
- The health system impact of false positive newborn screening results for medium-chain acyl-CoA dehydrogenase deficiency: a cohort study. Issue 1 (December 2016)
- Main Title:
- The health system impact of false positive newborn screening results for medium-chain acyl-CoA dehydrogenase deficiency: a cohort study
- Authors:
- Karaceper, Maria
Chakraborty, Pranesh
Coyle, Doug
Wilson, Kumanan
Kronick, Jonathan
Hawken, Steven
Davies, Christine
Brownell, Marni
Dodds, Linda
Feigenbaum, Annette
Fell, Deshayne
Grosse, Scott
Guttmann, Astrid
Laberge, Anne-Marie
Mhanni, Aizeddin
Miller, Fiona
Mitchell, John
Nakhla, Meranda
Prasad, Chitra
Rockman-Greenberg, Cheryl
Sparkes, Rebecca
Wilson, Brenda
Potter, Beth - Abstract:
- Abstract Background There is no consensus in the literature regarding the impact of false positive newborn screening results on early health care utilization patterns. We evaluated the impact of false positive newborn screening results for medium-chain acyl-CoA dehydrogenase deficiency (MCADD) in a cohort of Ontario infants. Methods The cohort included all children who received newborn screening in Ontario between April 1, 2006 and March 31, 2010. Newborn screening and diagnostic confirmation results were linked to province-wide health care administrative datasets covering physician visits, emergency department visits, and inpatient hospitalizations, to determine health service utilization from April 1, 2006 through March 31, 2012. Incidence rate ratios (IRRs) were used to compare those with false positive results for MCADD to those with negative newborn screening results, stratified by age at service use. Results We identified 43 infants with a false positive newborn screening result for MCADD during the study period. These infants experienced significantly higher rates of physician visits (IRR: 1.42) and hospitalizations (IRR: 2.32) in the first year of life relative to a screen negative cohort in adjusted analyses. Differences in health services use were not observed after the first year of life. Conclusions The higher use of some health services among false positive infants during the first year of life may be explained by a psychosocial impact of false positive resultsAbstract Background There is no consensus in the literature regarding the impact of false positive newborn screening results on early health care utilization patterns. We evaluated the impact of false positive newborn screening results for medium-chain acyl-CoA dehydrogenase deficiency (MCADD) in a cohort of Ontario infants. Methods The cohort included all children who received newborn screening in Ontario between April 1, 2006 and March 31, 2010. Newborn screening and diagnostic confirmation results were linked to province-wide health care administrative datasets covering physician visits, emergency department visits, and inpatient hospitalizations, to determine health service utilization from April 1, 2006 through March 31, 2012. Incidence rate ratios (IRRs) were used to compare those with false positive results for MCADD to those with negative newborn screening results, stratified by age at service use. Results We identified 43 infants with a false positive newborn screening result for MCADD during the study period. These infants experienced significantly higher rates of physician visits (IRR: 1.42) and hospitalizations (IRR: 2.32) in the first year of life relative to a screen negative cohort in adjusted analyses. Differences in health services use were not observed after the first year of life. Conclusions The higher use of some health services among false positive infants during the first year of life may be explained by a psychosocial impact of false positive results on parental perceptions of infant health, and/or by differences in underlying health status. Understanding the impact of false positive newborn screening results can help to inform newborn screening programs in designing support and education for families. This is particularly important as additional disorders are added to expanded screening panels, yielding important clinical benefits for affected children but also a higher frequency of false positive findings. … (more)
- Is Part Of:
- Orphanet journal of rare diseases. Volume 11:Issue 1(2016)
- Journal:
- Orphanet journal of rare diseases
- Issue:
- Volume 11:Issue 1(2016)
- Issue Display:
- Volume 11, Issue 1 (2016)
- Year:
- 2016
- Volume:
- 11
- Issue:
- 1
- Issue Sort Value:
- 2016-0011-0001-0000
- Page Start:
- 1
- Page End:
- 9
- Publication Date:
- 2016-12
- Subjects:
- Neonatal screening -- Metabolic diseases -- Health services utilization
Rare diseases -- Periodicals
Genetic disorders -- Periodicals
Orphan drugs -- Periodicals
616 - Journal URLs:
- http://pubmedcentral.com/tocrender.fcgi?journal=401&action=archive ↗
http://www.ojrd.com/home/ ↗
http://link.springer.com/ ↗ - DOI:
- 10.1186/s13023-016-0391-5 ↗
- Languages:
- English
- ISSNs:
- 1750-1172
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 9889.xml